XIEJing 1,2 , HUXin 1 , YANGLi-ping 1
  • 1. Department of Pharmacy, Beijing Hospital, Ministry of Public Health, Beijing 100730, China;
  • 2. Department of Pharmacy, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;
Export PDF Favorites Scan Get Citation

Objective To evaluate anti-platelet effect of clopidogrel influenced by CYP2C19*17 polymorphism in patients with cardiovascular disease. Methods We electronically searched EMbase, PubMed, The Cochrane Library, ClinicalTrials.gov, CNKI, CBM, WanFang Data and VIP databases for cohort studies about the anti-platelet effect of clopidogrel influenced by CYP2C19*17 polymorphism in patients with cardiovascular disease from inception to October 2012. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data and evaluated the methodological quality of the included studies. Then meta-analysis was performed using the software Rev-Man 5.2. Results A total of seven studies involving 12 116 patients were finally included. Three were 5 579 CYP2C19*17 carriers and 6 538 non-carriers. The results of meta-analyses showed that, compared with the CYP2C19*17 non-carriers, lower rate of cardiovascular events (OR=0.85, 95%CI 0.73 to 0.99, P=0.03) and higher bleeding events (OR=1.25, 95%CI 1.05 to 1.50, P=0.01) were found in the CYP2C19*17 carriers. Conclusion CYP2C19*17 carriers is with lower cardiovascular events and higher bleeding events than the CYP2C19*17 non-carriers.

Citation: XIEJing, HUXin, YANGLi-ping. Impact of CYP2C19*17 Gene Polymorphisms on the Clinical Efficacy of Clopidogrel: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2014, 14(3): 271-276. doi: 10.7507/1672-2531.20140048 Copy

  • Previous Article

    Application Research on Machine Mixed Silicone Rubber and Alginate for the Oral Cavity Repair Impression
  • Next Article

    Efficacy of Early Use of Heparin for Thrombolytic Therapy on Patients with Acute Myocardial Infarction: A Systematic Review